Oral bacillus Calmette-Guérin vaccine against tuberculosis: Why not?

Memorias do Instituto Oswaldo Cruz

Volumn 109, Issue 6, 2014, Pages 838-845

  Monteiro Maia, Renata ^a   De Pinho, Rosa Teixeira ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

BCG; Intradermal; Mucosal; Oral; Tuberculosis; Vaccine

Indexed keywords

BCG VACCINE;

ADOLESCENT; ADULT; CHILD; HISTORY; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOID TISSUE; MUCOSAL IMMUNITY; NEWBORN; ORAL DRUG ADMINISTRATION; PROCEDURES; TUBERCULOSIS, PULMONARY; VACCINATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BCG VACCINE; CHILD; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNITY, MUCOSAL; IMMUNOLOGIC MEMORY; INFANT, NEWBORN; LYMPHOID TISSUE; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 84907192197     PISSN: 00740276     EISSN: 16788060     Source Type: Journal    
DOI: 10.1590/0074-0276140091     Document Type: Article

References (61)

1. Assis A 1950. Novas perspectivas da vacinação contra a tuberculose pelo BCG. O Hospital XXXVIII: 337-353
2. Badell E, Nicolle F, Clark S, Majlessi L, Boudou F, Martino A, Castello-Branco L, Leclerc L, Lewis DJM, Marsh PD, Gicquel B, Winter N 2009. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-γ producing T-cells. Vaccine 27: 28-37.
3. Benévolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-Branco LRR 2005. BCG Moreau Rio de Janeiro - An oral vaccine against tuberculosis - Review. Mem Inst Oswaldo Cruz 100: 459-465.
4. Blazevic A, Eickhoff CS, Stanley J, Buller MR, Schriewer J, Kettleson EM, Hoft DF 2014. Investigations of TB vaccine-induced mucosal protection in mice. Microbes Infect 16: 73-79.
5. Bold TD, Ernst JD 2012. CD4+ T cell-dependent IFN-γ production by CD8+ effector T cells in Mycobacterium tuberculosis infection. J Immunol 189: 2530-2536.
6. Brosch R, Gordon SV, Garnier T, Eiglmeier K, Frigui W, Valenti P, dos Santos S, Duthoy S, Lacroix C, Garcia-Pelayo C, Inwald JK, Golby P, Garcia JN, Hewinson RG, Behr MA, Quail MA, Churcher C, Barrell BG, Parkhill J, Cole ST 2007. Genome plasticity of BCG and impact on vaccine efficacy. PNAS 104: 5596-5601.
7. Burl S, Adetifa UJ, Cox M, Touray E, Ota MO, Marchant A, Whittle H, McShane H, Rowland-Jones SL, Flanagan KL 2010. Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces post-vaccination TH1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 185: 2620-2628.
8. Clark SO, Kelly DL, Badell E, Castello-Branco LR, Aldwell F, Winter N, Lewis D, Marsh PD 2010. Oral delivery of BCG Moreau Rio de Janeiro gives equivalent protection against tuberculosis but with reduced pathology compared to parenteral BCG Danish vaccination. Vaccine 28: 7109-7116.
9. Cosgrove CA, Castello-Branco LR, Hussell T, Sexton A, Giemza R, Phillips R, Williams A, Griffin GE, Dougan G, Lewis DJ 2006. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Rio de Janeiro oral vaccine. Infect Immun 74: 2449-2452.
10. Costa AC, Nogueira SV, Kipnis A, Kipnis APJ 2014. Recombinant CG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol 5: 152.
11. Cross ML, Lambeth MR, Aldwell FE 2008. Murine cytokine responses following multiple oral immunizations using lipid-formulated mycobacterial antigens. Immunol Cell Biol 86: 214-217.
12. Esmail H, Barry CE, Young DB, Wilkinson RJ 2014. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 369: 1-14.
13. Felber A, Graninger W 2013. Weakly positive tests and chronologic variation of the QuantiFERON assay: a retrospective appraisal of usefulness. Tuberculosis (Edinb) 93: 647-653.
14. Fujkuyama Y, Tokuhara D, Kataoka K, Gilbert RS, McGhee JR, Yuki Y, Kiyono H, Fujihashi K 2012. Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines 11: 367-379.
15. Gan C, Mostafid H, Kha MS, Lewis DJM 2013. BCG immunotherapy for bladder cancer - the effects of substrain differences. Nat Rev Urol 10: 580-588.
16. Gheorghiu M 1996. Le BCG, vaccin contre la tuberculose: leçons du passé pour aujourd’hui. In AM Moulin, L’Aventure de la vaccination, Fayard, Paris, p. 219-228.
17. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, Winata E, Swarbrick GM, Chua WJ, Yu YY, Lantz O, Cook MS, Null MD, Jacoby DB, Harriff MJ, Lewinsohn DA, Hansen TH, Lewinsohn DM 2010. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol 8: e1000407.
18. Gomes LHF, Otto TD, Vasconcellos EA, Ferrão PM, Maia RM, Moreira AS, Ferreira MA, Castello-Branco LRR, Degrave WM, Mendonça-Lima L 2011. Genome sequence of Mycobacterium bovis BCG Moreau, the Brazilian vaccine strain against tuberculosis. J Bacteriol 193: 5600-5601.
19. Gröschel MI, Prabowo SA, Cardona PJ, Stanford JL, Van der Werf TS 2014. Therapeutic vaccines for tuberculosis - a systematic review. Vaccine 32: 3162-3168.
20. Hawkridge A 2009. Clinical studies of TB vaccines. Hum Vaccin 5: 773-776.
21. Heimbeck J 1948. BCG vaccination of nurses. Tubercle April: 84-88.
22. Ho MM, Southern J, Kang HN, Knezevic I 2010. WHO informal consultation on standardization and evaluation of BCG vaccines Geneva, Switzerland 22-23 September 2009. Vaccine 28: 6945-6950.
23. Hoft DF, Brown RM, Belshe RB 2000. Mucosal bacille Calmette-Guérin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative, but induces mycobacteria-specific interferon-gamma responses. Clin Infect Dis 30 (Supplement 3): S217-S222.
24. Holmgren J, Czerkinsky C, Eriksson K, Mharandi A 2003. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 21 (Supplement 2): S2/89-S2/95.
25. Holmgren J, Svennerholm AM 2012. Vaccines against mucosal infections. Curr Opin Immunol 24: 343-353.
26. Honda I, Seki M, Ikeda N, Yamamoto S, Yano I, Koyama A, Toida I 2006. Identification of two subpopulations of bacillus Calmette-Guérin (BCG) Tokyo 172 substrain with different RD16 regions. Vaccine 24: 4969-4974.
27. Kahnert A, Seiler P, Stein M, Bandermann S, Hahnke K, Mollenkopf H, Kaufmann SH 2006. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur J Immunol 36: 631-647.
28. Kashyap RS, Husain AA, Morey SH, Panchbhai MS, Deshpande PS, Purohit HJ, Taori GM, Daginawala HF 2010. Assessment of immune response to repeat stimulation with BCG vaccine using in vitro PBMC model. J Immune Based Ther Vaccines 8: 3.
29. Kaufmann SH 2010. Novel tuberculosis vaccination strategies based on understanding the immune response. J Intern Med 267: 337-353.
30. Kaufmann SH 2013. Tuberculosis vaccines: time to think about the next generation. Semin Immunol 25: 172-181.
31. Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, Cilley GE, Shen F, Eaton SM, Gaffen SL, Swain SL, Locksley RM, Haynes L, Randall TD, Cooper AM 2007. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369-377.
32. Kim SH, Lee KY, Jang YS 2012. Mucosal immune system and M cell-targeting strategies for oral mucosal vaccination. Immune Netw 12: 165-175.
33. Lagranderie M, Chavarot P, Balazuc AM, Marchal G 2000. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 18: 1186-1195.
34. Li Q, Li J, Tian J, Zhu B, Zhang Y, Yang K, Ling Y, Hu Y 2012. IL-17 and IFN-γ production in peripheral blood following BCG vaccination and Mycobacterium tuberculosis infection in human. Eur Rev Med Pharmacol Sci 16: 2029-2036.
35. Ling WL, Wang LJ, Pong JCH, Lau ASY, Li JCB 2013. A role for interleukin-17A in modulating intracellular survival of Mycobacterium bovis bacillus Calmette-Guérin in murine macrophages. Immunology 140: 323-334.
36. Liu J, Tran V, Leung AS, Alexander DC, Zhu B 2009. BCG vaccines. Their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 5: 70-78.
37. Lycke N 2012. Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol 12: 592-605.
38. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PEM, Rodrigues LC, Smith PG, Lipman M, Whiting PF, Sterne JA 2014. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58: 470-480.
39. Meraviglia S, El Daker S, Dieli F, Martini F, Martino A 2011. γδ T cells cross-link innate and adaptive immunity in Mycobacterium tuberculosis infection. Clin Dev Immunol 2011: 11.
40. Monteiro-Maia R, Ortigão-de-Sampaio MB, Pinho RT, Castello-Branco LR 2006. Modulation of humoral immune response to oral BCG vaccination by Mycobacterium bovis BCG Moreau Rio de Janeiro (RDJ) in healthy adults. J Immune Based Ther Vaccines 6: 4.
41. Ordway DJ, Martins MS, Costa LM, Freire MS, Arroz MJ, Dockrell HM, Ventura FA 2005. Increased IL-4 production in response to virulent Mycobacterium tuberculosis in tuberculosis patients with advanced disease. Acta Med Port 18: 27-36.
42. Ottenhoff THM, Kaufmann SHE 2012. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8: e1002607.
43. Owen JL, Sahay B, Mohamadzadeh M 2013. New generation of oral mucosal vaccines targeting dendritic cells. Curr Opin Chem Biol 17: 918-924.
44. Pavot V, Rochereau N, Genin C, Verrier B, Paul S 2012. New insights in mucosal vaccine development. Vaccine 30: 142-154.
45. Ranasinghe C 2014. New advances in mucosal immunization. Immunol Lett doi: 10.1016/j.imlet.2014.01.006.
46. Rhee JH, Lee SE, Kim JY 2012. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 1: 50-63.
47. Sada-Ovalle I, Chiba A, Gonzales A, Brenner MB, Behar SM 2008. Innate invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, produce interferon-γ and kill intracellular bacteria. PLoS Pathog 4: e1000239.
48. Sato S, Kiyono H 2012. The mucosal immune system of the respiratory tract. Curr Opin Virol 2: 225-232.
49. Schreiber F, Huo Z, Giemza R, Woodrow M, Fenner N, Stevens Z, Dougan G, Prideaux S, Castello-Branco LRR, Lewis DJM 2010. An investigation of clinical and immunological events following repeated aerodigestive tract challenge infections with live Mycobacterium bovis bacille Calmette-Guérin. Vaccine 28: 5427-5431.
50. Sebina I, Cliff JM, Smith SG, Nogaro S, Webb EL, Riley EM, Dockrell HM, Elliott AM, Hafalla JC, Cose S 2012. Long-lived memory B-cell responses following BCG vaccination 2012. PLoS ONE 7: e51381.
51. Succi RCM 1985. BCG. In CK Farhat, Fundamentos e prática das imunizações em clínica médica e pediatria, Atheneu, Rio de Janeiro, p. 27-41.
52. Tameris MD, Mc Shane H, Mc Clain JB, Landry B, Lochhart S, Luabeya AK, Geldenhuys H, Shea J, Hussey G, van der Merwe L, de Kock M, Scriba T, Walker R, Hanekom W, Hatherill R, Mahomed H 2013. Lessons learnt from the first efficacy trial of a new infant tuberculosis vaccine since BCG. Tuberculosis (Edinb) 93: 143-149.
53. Thakur A, Pedersen LE, Jungersen G 2012. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine 30: 4907-4920.
54. Valadas E 2004. Nontuberculous mycobacteria: clinical importance and relevance to bacille Calmette-Guérin vaccination. Clin Infect Dis 39: 457-458.
55. Vipond J, Cross ML, Lambeth MR, Clark S, Aldwell FE, Williams A 2008. Immunogenicity of orally-delivered lipid-formulated BCG vaccines and protection against Mycobacterium tuberculosis infection. Microbes Infect 10: 1577-1581.
56. Wang D, Xu J, Feng Y, Liu Y, Mchenga SS, Shan F, Sasaki J, Lu C 2010. Liposomal oral DNA vaccine (mycobacterium DNA) elicits immune response. Vaccine 28: 3134-3142.
57. Weiner J, Kaufmann SHE 2014. Recent advances towards tuberculosis control: vaccines and biomarkers. J Intern Med 275: 467-480.
58. WHO - World Health Organization 2013. Global tuberculosis report 2013. Available from: who.int/tb/publications/global_report/en/.
59. Woodrow KA, Bennett KM, Lo DD 2012. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 14: 17-46.
60. Zaman M, Chandrudu S, Toth I 2013. Strategies for intranasal delivery of vaccines. Drug Deliv Transl Res 3: 100-109.
61. Zhang W, Zhang Y, Zheng H, Pan Y, Liu H, Du P, Wan L, Liu J, Zhu B, Zhao G, Chen C, Wan K 2013. Genome sequencing and analysis of BCG vaccine strains. PLoS ONE 8: e71243.